


RAI Services Company

Michael W. Ogden, Ph.D.
Senior Vice President
Scientific & Regulatory Affairs
Winston-Salem, NC 27101
336-741-5787
Fax: 336-728-7675
ogdenm@rjrt.com

CONFIDENTIAL, NOT FOR PUBLIC DISCLOSURE

February 6, 2018



Ann Simoneau
Director, Office of Compliance and Enforcement
Food and Drug Administration
Center for Tobacco Products
Document Control Center (DCC)
Building 71, Room G335
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

Re: Response to Office of Compliance and Enforcement request for MR0000068 Camel Snus Frost; MR0000069 Camel Snus Frost Large; MR0000070 Camel Snus Mellow; MR0000071 Camel Snus Mint; MR0000072 Camel Snus Robust; MR0000073 Camel Snus Winterchill

Dear Ms. Simoneau:

RAI Services Company ("RAIS")¹ hereby submits the following, on behalf of R.J. Reynolds Tobacco Company ("RJRT"), in response to the United States Food and Drug Administration's ("FDA") Center for Tobacco Products ("CTP") January 24, 2018, INSPECTION REQUEST letter regarding RAIS' submission of Applications Seeking a Modified Risk Tobacco Product Order ("MRTP Applications"), submitted under Section 911(d) of the Food, Drug, and Cosmetic Act ("FDCA") on March 30, 2017 for the following tobacco products:

- Camel Snus Frost (MR0000068);
- Camel Snus Frost Large (MR0000069);
- Camel Snus Mellow (MR0000070);
- Camel Snus Mint (MR0000071);
- Camel Snus Robust (MR0000072);

¹ RAI Services Company ("RAIS") bears primary responsibility for regulatory compliance for Reynolds American Inc.'s operating companies, including R.J. Reynolds Tobacco Company ("RJRT"), American Snuff Co., LLC ("ASC"), Santa Fe Natural Tobacco Company, Inc. ("SFNTC"), and R.J. Reynolds Vapor Company. References to RAIS in this letter refer to itself and its affiliated companies where applicable.


- Camel Snus Winterchill (MR0000073).

This letter includes responses to items #1 and #2 from FDA's January 24, 2018 letter which request that certain information be provided to FDA. In this response, we have repeated CTP's requests, verbatim and in bold italics, followed by RAIS' response.

Please note that the enclosed response may contain confidential commercial and non-public trade secret information belonging to RAIS, RJRT, or RJRT's vendors. All such confidential and trade secret information is exempt from public disclosure under § 301(j) and § 906(c) of the FDCA, 5 U.S.C. § 552(b)(4), 18 U.S.C. § 1905, and 21 C.F.R. § 20.61 and any similar or related laws and regulations. RAIS and RJRT respectfully request that FDA maintain the confidentiality of this information.

RAIS looks forward to the opportunity for this inspection. Please let us know FDA's preferred dates for the inspection and we will make any necessary final arrangements. Should you have any questions or require any additional information, please contact me at your earliest convenience.

Respectfully submitted,



Michael W. Ogden, Ph.D.
Senior Vice President
Scientific & Regulatory Affairs
RAI Services Company